skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

Cities across the nation are organizing Moving Day as part of a community awareness program initiated by the National Parkinson’s Foundation. Movement is a symbol of hope and progress because of its essential role in treating Parkinson’s. Many people have a loved one or know someone afflicted with Parkinson’s disease. Statistics show that, to date, 1 million people have been diagnosed with Parkinson’s in the US, and more than 5 million diagnosed worldwide, with the number of new diagnoses expected to dramatically increase each year with our aging population. This is of great concern because there is still no disease modifying therapy available to treat the cause of Parkinson’s or delay disease progression, only drugs that treat the symptoms.  The standard therapies, such as levodopa/carbidopa, have limitations and side effects, while newer drugs such as dopamine agonists, monoamine oxidase (MAO)inhibitors, and catechol-o-methyltransferase (COMT) inhibitors, have not proven as efficacious as originally anticipated.  

So what is the outlook for the future of Parkinson’s? The following report will provide insight into the current clinical development landscape, which offers hope for potential new therapies in the near future and beyond.

お問い合わせ&レポートストア

専任スタッフによるデモンストレーションを兼ねたサービスの詳しいご説明、または無料トライアルを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。

*一部のサービスでは無料トライアルをご利用になれません。

ご質問等ございましたらお気軽にご連絡下さい。

日本(平日:9時~18時)
電話:+81 (0)3 6273 4260
Email:inquiry.jp@informa.com

オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。

お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。